- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Asthma and chronic obstructive pulmonary disease (COPD)
- Meeting Date: November 2023
- Public Summary Document (PSD) November 2023 PBAC Meeting - (PDF 564KB)
- Public Summary Document (PSD) November 2023 PBAC Meeting - (Word 136KB)
Budesonide + formoterol – November 2023
Budesonide + Formoterol: Powder for oral inhalation in breath actuated device containing budesonide 200 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 60 doses, Powder for oral inhalation in breath actuated device containing budesonide 400 micrograms with formoterol fumarate dihydrate 12 micrograms per dose, 60 doses; Bufomix® Easyhaler®
Last updated
1 March 2024
